BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32680650)

  • 21. Overcoming epithelial-mesenchymal transition-mediated drug resistance with monensin-based combined therapy in non-small cell lung cancer.
    Ochi K; Suzawa K; Tomida S; Shien K; Takano J; Miyauchi S; Takeda T; Miura A; Araki K; Nakata K; Yamamoto H; Okazaki M; Sugimoto S; Shien T; Yamane M; Azuma K; Okamoto Y; Toyooka S
    Biochem Biophys Res Commun; 2020 Aug; 529(3):760-765. PubMed ID: 32736704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery.
    Jin H; He Y; Zhao P; Hu Y; Tao J; Chen J; Huang Y
    Theranostics; 2019; 9(1):265-278. PubMed ID: 30662566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
    Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
    Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
    Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.
    Sakamoto T; Kobayashi S; Yamada D; Nagano H; Tomokuni A; Tomimaru Y; Noda T; Gotoh K; Asaoka T; Wada H; Kawamoto K; Marubashi S; Eguchi H; Doki Y; Mori M
    PLoS One; 2016; 11(1):e0145985. PubMed ID: 26726879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Luteolin and cancer metastasis suppression: focus on the role of epithelial to mesenchymal transition.
    Hussain Y; Cui JH; Khan H; Aschner M; Batiha GE; Jeandet P
    Med Oncol; 2021 May; 38(6):66. PubMed ID: 33950369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer.
    Huang RY; Chung VY; Thiery JP
    Curr Drug Targets; 2012 Dec; 13(13):1649-53. PubMed ID: 23061545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc.
    Chen D; Huang J; Zhang K; Pan B; Chen J; De W; Wang R; Chen L
    Eur J Cancer; 2014 Nov; 50(17):3050-67. PubMed ID: 25310895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The tumor microenvironment: An irreplaceable element of tumor budding and epithelial-mesenchymal transition-mediated cancer metastasis.
    Li H; Xu F; Li S; Zhong A; Meng X; Lai M
    Cell Adh Migr; 2016 Jul; 10(4):434-46. PubMed ID: 26743180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the Overexpressed YY1 in Cancer Inhibits EMT and Metastasis.
    Cho AA; Bonavida B
    Crit Rev Oncog; 2017; 22(1-2):49-61. PubMed ID: 29604936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.
    Fischer KR; Durrans A; Lee S; Sheng J; Li F; Wong ST; Choi H; El Rayes T; Ryu S; Troeger J; Schwabe RF; Vahdat LT; Altorki NK; Mittal V; Gao D
    Nature; 2015 Nov; 527(7579):472-6. PubMed ID: 26560033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Microenvironment of Lung Cancer and Therapeutic Implications.
    Mittal V; El Rayes T; Narula N; McGraw TE; Altorki NK; Barcellos-Hoff MH
    Adv Exp Med Biol; 2016; 890():75-110. PubMed ID: 26703800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells.
    Lee AF; Chen MC; Chen CJ; Yang CJ; Huang MS; Liu YP
    PLoS One; 2017; 12(7):e0180383. PubMed ID: 28683123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TEAD4: A key regulator of tumor metastasis and chemoresistance - Mechanisms and therapeutic implications.
    Liu M; Hu W; Meng X; Wang B
    Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189050. PubMed ID: 38072284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PHD3 Controls Lung Cancer Metastasis and Resistance to EGFR Inhibitors through TGFα.
    Dopeso H; Jiao HK; Cuesta AM; Henze AT; Jurida L; Kracht M; Acker-Palmer A; Garvalov BK; Acker T
    Cancer Res; 2018 Apr; 78(7):1805-1819. PubMed ID: 29339541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteomic analysis of ovarian cancer cells during epithelial-mesenchymal transition (EMT) induced by epidermal growth factor (EGF) reveals mechanisms of cell cycle control.
    Grassi ML; Palma CS; Thomé CH; Lanfredi GP; Poersch A; Faça VM
    J Proteomics; 2017 Jan; 151():2-11. PubMed ID: 27394697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting metabolic flexibility via angiopoietin-like 4 protein sensitizes metastatic cancer cells to chemotherapy drugs.
    Lim MMK; Wee JWK; Soong JC; Chua D; Tan WR; Lizwan M; Li Y; Teo Z; Goh WWB; Zhu P; Tan NS
    Mol Cancer; 2018 Oct; 17(1):152. PubMed ID: 30342537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer.
    Garg M
    Expert Opin Ther Targets; 2015 Feb; 19(2):285-97. PubMed ID: 25563894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.